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Summary We have previously reported on the efficacy of intraperitoneal (i.p.) immunotherapy with
interleukin-2 (IL-2) and adoptively transferred lymphokine activated killer (LAK) cells in an i.p. murine
tumour model. Because of a dose-limiting toxicity associated with IL-2, cures are seldom observed. The
development of treatment strategies that combine components that augment or synergise with the antitumour
activity of IL-2 is crucial for the successful use of IL-2 in a clinical setting. Because of the known toxicity of
high-dose IL-2 or high dose cyclophosphamide (CY) treatment, the goal of our experiments was to investigate
the efficacy of chemoimmunotherapy with low or moderate doses of cyclophosphamide (CY) in combination
with low or moderate doses of IL-2 with or without adoptively transferred LAK cells. Assessment of i.p.
tumour growth 14 days after tumour inoculation, using the peritoneal cancer index (PCI) scoring system,
demonstrated that combination treatment of established (day 3) i.p. tumour was clearly superior to single
modality treatment. The effect was further enhanced by a second dose of CY at the end of a course of IL-2.
Combination treatment led to a significant survival benefit. About 25% of the mice were cured, even when
the dose of tumour cells at inoculation was increased. These experiments demonstrate the efficacy of
combined treatment with IL-2, LAK cells and CY. Further research should be directed at the design of
treatment schedules based on repetitive courses of chemoimmunotherapy associated with little toxicity.
Adoptive immunotherapy with lymphokine activated killer
(LAK) cells and interleukin-2 (IL-2) has been shown effec-
tive in the treatment of established metastatic pulmonary,
hepatic, and intraperitoneal (i.p.) tumour in the mouse (Mule
et al., 1984; Lafreniere & Rosenberg, 1985; Ottow et al.,
1987a). The results of immunotherapy with IL-2 and LAK
in patients with advanced cancer are encouraging and under-
line the potential of this new approach to the treatment of
cancer (Rosenberg et al., 1987; West et al., 1987). LAK cells
are lymphoid cells that have acquired the capacity to lyse
fresh tumour cells in 4 hour 51Chromium release assays
(Grimm et al., 1982). This can be achieved in vitro by a three
day incubation in IL-2 and in vivo by administration of high
doses of IL-2 (Ettinghausen et al., 1985). We have recently
shown that the generation of LAK cell activity in the
peritoneal exudate by the administration of IL-2 is particu-
larly effective (Ottow et al., 1987b; Eggermont et al., 1988).
Unfortunately the toxicity of high doses of IL-2 is a major
obstacle to obtain cures with interleukin-2. This has brought
us to explore various treatment strategies that will augment
antitumour effects of IL-2 (Eggermont et al., 1987a). An
attractive feature of adoptive immunotherapy with IL-2 and
LAK cells is its efficacy in the immunocompromised host
(Mule et al., 1985). Combination therapy with cytostatic
agents should therefore be feasible. Here we report on the
results of our investigations concerning the efficacy of com-
bination treatment schedules using cyclophosphamide (CY),
IL-2 and LAK cells against established tumour in an i.p.
murine tumour model.
Materials and methods
Mice
C57BL/6 (BL/6) female mice were obtained from Jackson
Laboratory (Bar Harbor, ME) and used when 9-12 weeks
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old. They were maintained on laboratory chow and acidified
water ad libitum in a pathogen-free environment.
Tumour
The MCA-105 sarcoma used in these experiments was
induced in our laboratory by the i.m. injection of 0.1 ml of
1% 3-methylcholanthrene (MCA) in sesame oil as described
previously (Parker & Rosenberg, 1977). A large number of
vials from the first passage generation were cryopreserved.
After thawing, the tumour was passaged subcutaneously and
its use was restricted to the first 6 passage generations.
Single cell suspensions of the tumour were prepared as
described previously (Mule et al., 1984). Briefly, fresh
tumours were excised, minced with scissors and stirred in a
triple enzyme solution of deoxyribonuclease, hyaluronidase
and collagenase (Sigma Chemical Co., St Louis, MO) for 3 h
at room temperature, filtered through 100 gauge nylon mesh
(Nitex, Lawshe Industrial Co., Bethesda, MD), washed three
times in Hanks balanced salt solution (HBSS; Biofluids,
Rockville, MD) without calcium (Ca2+) and magnesium
(Mg2+) and resuspended at the appropriate cell concen-
tration for injection in HBSS. In all experiments described
here single cell suspensions of sarcoma MCA-105 were used.
MCA-105 is a weakly immunogenic sarcoma (Papa et al.,
1986).
Interleukin-2
Human recombinant interleukin-2 was kindly supplied by
the Cetus Corporation (Emeryville, CA) and had a specific
activity of 3-4 x 106 units of IL-2mg-I protein (Rosenberg
et al., 1984). IL-2 activity was measured by a standard
bioassay as described previously (Donahue & Rosenberg,
1983). IL-2 was used for the preparation of LAK cells and
for i.p. administration.
Cyclophosphamide (Cytoxan; CY)
Cyclosphamide was purchased from Mead and Johnson Co.
(Evansville, IN). It was dissolved in sterile water to a
concentration of 200mgml-1 and further diluted with HBSS
to a concentration depending on experimental design.
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Generation of LAK cells
LAK cells were generated as described previously (Mule et
al., 1984). Briefly: BL/6 spleens were harvested aseptically
and mashed in HBSS with the hub of a syringe and passed
through a 100 gauge nylon mesh (Nitex) to produce a single
cell suspension. Erythrocytes were lysed osmotically with
ACK buffer (Media Unit, NIH, Bethesda, MD). The
remaining splenocytes were washed three times in HBSS and
5 x 108 cells were incubated in culture flasks containing
175ml complete medium (CM) and 175,000 units IL-2 per
flask. Complete medium contained RPMI 1640 with 10%
foetal calf serum (both Biofluids, Rockville, MD), 0.3%
fresh glutamine, 100 ugml-l streptomycin, 100 unitsml-l
penicillin (all from the NIH Media Unit), 0.1 mm non-
essential amino acids, 0.1 mM sodium pyruvate (all from
Gibco Laboratories, Grand Island, NY), 5 x 10-5 2-
mercapto-ethanol (Aldridge Chemical Co., Milwaukee, WI),
50,g ml 1 gentamicin (Shearing, Kenilworth, NJ), and
0.5 ygml-1 fungizone (Flow Labs, McLean, VA). The flasks
were incubated for 72h at 37°C in a moist atmosphere with
5% CO2. The LAK cells were then harvested, washed three
times and resuspended in HBSS for i.p. administration.
Intraperitoneal tumour model
BL/6 mice received 1 x 105 MCA-105 tumur cells i.p. and
were randomly allocated into a treatment group. Three days
after tumour inoculation 1 x 108 LAK cells were given i.p.
and depending on experimental design 10,000 or 25,000 units
of IL-2 were adminsitered i.p. from day 3 through 7 twice a
day (b.i.d.). CY was given at different doses on day 3, 8 or 3
and 8 depending on experimental design. About 14 days
after tumour inoculation the mice were sacrificed and the i.p.
tumour mass was scored in a blinded fashion on a scale
from 0-3. The scoring system was called the peritoneal
cancer index (PCI) (Ottow et al., 1987a). The mice were
eartagged and their numbers recorded prior to scoring. The
abdomen of all mice was opened widely and scored for
tumour load. A score of 0 is defined as no i.p. tumour, 1 as
<3 pin point tumour foci (diameter 1 mm), 2 as moderate
i.p. tumour and 3 as abundant i.p. tumour replacing most of
the peritoneal cavity. After all mice were scored the ear tag
was read and the data analyzed. In the peritoneal cancer
index experiments each experimental group consisting of at
least 6 mice were inoculated with 1 x 105 tumour cells. In the
survival experiments mice were inoculated with 1 x 105 or
3 x 105 tumour cells. Experimental groups consisted of 12-24
mice.
Statistical analysis
Overall significance of difference in the i.p. tumour experi-
ments was examined with the Jonckheere test for trend
(Holland & Wolfe, 1973). If this test showed a two sided P
value .0.05, pairwise comparisons of differences in tumour
load were examined with the Wilcoxon rank sum test with a
correction for ties (Gehan, 1965). Two-sided P-values are
presented in all experiments.
Results
Tumour reduction by cyclophophamide is dose dependent
First a dose finding study with CY was performed. BL/6
mice were inoculated i.p. with 1 x 105 MCA-105 tumour
cells. On day 3, 8 or day 3 and 8 different doses of CY,
ranging from 10mgkg- 1 up to 75mgkg-' were given i.p.
The mice were sacrificed on day 14 and the i.p. tumour load
was scored blindly using the PCI scoring system. The results
are summarized in Table I. Tumour reduction by CY was
clearly dose dependent. In most experiments a significant
reduction of i.p. tumour was achieved when doses of
50mgkg-1 or higher were given on day 3. The adminis-
tration of this dose on day 8 had little if any effect. When
doses of 50mgkg 1 or higher were given on day 3 and day
8 a significant tumour reduction was seen in all experiments.
Chemoimmunotherapy with cyclophosphamide and IL-2+LAK
is superior to either treatment modality alone
BL/6 mice were inoculated with 1 x 105 MCA-105 tumour
cells. On day 3, or on day 3 and 8, CY (50mgkg-1) was
given i.p. On day 3 CY was always given 12h prior to the
administration of IL-2 and LAK cells. IL-2 was administered
every 12h from day 3 through 7 at a dose of 10,000 or
25,000 units depending on experimental design. LAK cells
(1 x 108) were given i.p. on day 3. Control animals received
equal volumes of HBSS as was required for the adminis-
tration of CY, IL-2 or LAK cells. On day 14 the mice were
sacrificed and their i.p. tumour load was scored in a blind
fashion.
The results are summarized in Tables II and III.
In Table II the PCI scores are listed concerning the effects
of a single administration of CY on day 3 in conjunction
with IL-2 and LAK cells.
Table III illustrates the effects after the administration of
CY on day 3 and 8 in conjunction with IL-2 and LAK.
Treatment with 10,000 units of IL-2 i.p. b.i.d. alone did not
reduce i.p. tumour significantly in any experiment, whereas
the combination of IL-2 with the adoptive transfer of 1 x 108
LAK cells i.p. reduced i.p. tumour significantly in all
experiments. The tumour reducing effect of a single dose of
CY on day 3 was remarkably enhanced by a second dose on
day 8, even though a single dose on day 8 had no effect.
Table I Effect of different doses of cyclophosphamide on intraperitoneal tumour growth (mean
PCI +s.e.m.)
Exp. Day Control Day 3 Day 8 Days 3-8
1 10mgkg-1 2.75+0.13 2.67+0.21 2.50+0.22 2.83+0.17
2 25mgkg-1 2.75+0.11 2.67+0.21 2.50+0.34 2.17+0.27
3 50mgkg-1 2.86+0.10 2.00+0.26 - 1.33+0.33
(0.004) (0.0003)
4 50mgkg-1 2.80+0.09 2.50+0.22 2.83+0.17 1.17+0.31
(0.0002)
5 75mgkg-1 2.75+0.11 1.50+0.43 2.17+0.40 0.33+0.14
(0.005) (0.000005)
PCI =Peritoneal Cancer Index; s.e.m. =standard error of the mean; cyclophosphamide=CY;
P2 values of pairwise comparisons with control animals are indicated between brackets when
the PCI of the experimental group was significantly different from the PCI of the control group.
The mice were inoculated with 1 x 105 MCA-105 tumour cells on day 0 and treated with CY at
different doses on day 3 or day 8 or on day 3 and 8, as indicated. The mice were sacrificed 14
days after i.p. tumour inoculation and their i.p. tumour load was scored with the PCI-scoring
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Table II Cyclophosphamide on day 3 and IL-2+LAK (mean PCI+ s.e.m.)
Exp. Control CY day 3 IL-2 IL-2/CY IL-2+LAK IL-2+LAK/CY
1 2.83+ 0.11 2.50+0.22 2.83+0.17 2.33+ 0.21 2.33 +0.21 2.00+0.26
(NS) (NS) (P2 <0.05) (P2 <0.05) (P2 <0.008)
2 2.87+0.09 1.83 +0.31 2.33 +0.33 1.67+0.21 2.00+0.26 0.50+0.21
(P2 <0.002) (NS) (P2 <0.0002) (P2 <0.002) (P2 <0.00005)
S~~~~~~~~~~~~~ P <0.006 P2
P2 <0.02
3 2.86+0.10 2.09+0.23 2.83+0.17 1.83+0.17 1.50+0.34 1.00+0.26
(P2 <0.02) (NS) (P2 <0.0005) (P20.002) (P2 <0.0002)
I ~ ~ ~ ~ ~ ~ ~~~I I I
P <P0.007 NS<00 ~~~~~~~~~2
'~ ~ ~~~~~ P<0.01
PCI Peritoneal Cancer Index; s.e.m. =standard error of the mean; P2-values of pairwise comparisons with
control animals are indicated between brackets. P2-values of pairwise comparisons between various treated
groups are shown without brackets. Animals were treated with cyclophosphamide (CY) on day 3, 12h prior to
treatment with I x 108 LAK cells, i.p. on day 3, and/or IL-2, i.p. 10,000 Units, b.i.d., day 3 through 7. Fourteen
days after i.p. tumour inoculation the mice were sacrificed and their i.p. tumour load was scored in a blind
fashion with the PCI-scoring system.
Table III Cyclophosphamide on day 3 and 8 and IL-2+LAK (mean PCI+s.e.m.)
Exp. Control CY 3, 8 IL-2 IL-2/CY3, 8 IL-2+LAK IL-2+LAK/CY3,8
1 2.83+0.11 1.83+0.31 2.83+0.17 1.83+0.31 2.33+0.21 1.17+0.17
(P2 <0.006) (P2 <0.006) (P2 <0.05) (P2 <0.0003)
LP2 <0.03 P2 <0.006+
P2 <0.09
2 2.86+0.09 0.83+0.21 2.33+0.33 0.33 +0.21 2.00+0.26 0.0+0
(P2 <0.00005) (NS) (P2<0.00005) (P2<0.002) (P2<0.00004)
P2 <0.005 P2 <0.002
P20.04
3 2.86+0.10 1.08+0.19 2.83+0.17 0.50+0.21
(P2 <0.00002) (NS) (P2 <0.0002)
P2<0.003-;
F-p 2 < 0.09
1.50+0.34 0.50+0.34
(P20.002) (P2 <0.0002)
L -P <0.06 2I
PCI = Peritoneal Cancer Index; s.e.m. =standard error of the mean; P2-values of pairwise comparisons with
control animals are indicated between brackets. P2-values of pairwise comparisons between various treated
groups are shown without brackets. Animals were treated with cyclophosphamide (CY) on day 3 and day 8. On
day 3 CY was administered 12h prior to treatment with 1 x 108 LAK cells, i.p. on day 3, and/or IL-2, i.p. 10,000
Units, b.i.d., day 3 through 7. Fourteen days after i.p. tumour inoculation the mice were sacrificed and their i.p.
tumour load was scored in a blind fashion with the PCI-scoring system.
Combination therapy with IL-2 alone or with IL-2 and LAK
cells was more effective than any single component therapy
in all experiments. In all experiments tumour reduction was
greatest when all three components, e.g., CY, IL-2 and LAK
cells were given. In 3 out of 4 experiments no tumour could
be detected by the naked eye on day 14 in any or most mice
treated with CY with IL-2 or CY with IL-2 and LAK cells.
As shown in Tables II and III, differences in tumour
reduction after CY, CY+IL-2, or CY + IL-2+LAK were not
always statistically significant. This is mainly due to the
crudeness of the scoring system. The overall trend of the
experiments is unmistakably that the more extensive the
combined treatment schedule, the more effective its tumour
reducing capacity. In order to validate these observations
survival experiments were performed.
Combination treatment of established tumour with CY and
IL-2 prolongs survival
BL/6 mice, inoculated with the usual dose of MCA-105 cell
i.p., were treated with intermediate doses of IL-2 (25,000
units, i.p., b.i.d.) and CY (50mgkg-I on day 3 and 8). A
distinct survival benefit was seen with combination treatment
(Figure 1). Two mice were long term survivors. After 100
days they were sacrificed and were found to have no visible
tumour i.p. upon examination.
Combination treatment with CY, IL-2 and LAK cells
prolongs survival most effectively after high dose tumour
inoculation
BL/6 mice, inoculated with 3 x 105 MCA-105 cells i.p. on
day 0, were treated with CY (50mgkg-I on day 3 and 8),
and/or IL-2 (25,000 units, i.p., b.i.d., from day 3 through 7)
and LAK cells (1 x 108 cells on day 3). IL-2 alone did not
prolong survival. The results of this experiment are depicted
in Figure 2. Treatment with CY alone, or IL-2 plus LAK
cells prolonged survival modestly. A distinct prolongation of
survival was seen when CY and IL-2 were combined, even
though with this high initial tumour load to permanent
survivors were seen. Twenty-five percent of the group of
mice that received CY, IL-2 and LAK cells were longtime
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Figure I Significant survival benefit after combination treatment
with cyclophosphamide and interleukin-2. BL/6 mice, inoculated
with 1 x 105 MCA-105 tumour cells i.p. on day 0, were treated
with IL-2 (25,000 Units, i.p., b.i.d.) from day 3 through 7 and/or
with cyclophosphamide (cytoxan) (50mgkg- , i.p.) on day 3
and on day 8. P2-values for the significance of pairwise compari-
sons are indicated in the right upper corner. It is clearly
demonstrated that the combination treatment with IL-2 and
cytoxan has a synergistic antitumour effect and leads to an
important survival benefit.
survivors (no i.p. tumour when autopsy was performed on
day 100). Combination treatment with all three components
was clearly much more effective than any other treatment
schedule.
Discussion
We have shown that chemoimmunotherapy with cyclo-
phosphamide and IL-2 or IL-2 plus LAK cells has superior
antitumour activity when compared to the effects of single
agent treatment. The combination of the two treatment
modalities has at least an additive if not a synergistic
antitumour effect. Low doses of CY in combination with a
cycle of intermediate doses of IL-2 resulted in a significant
survival benefit and even cured some mice with established
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i.p. tumour. The treatment of established i.p. tumour by
relatively low doses of IL-2 (10,000 units, b.i.d.) alone was
not effective but clearly enhanced the antitumour effect of
low doses (50mgkg-1) of CY or vice versa. The nature of
this phenomenon is unknown but several hypotheses to
explain the enhanced antitumour effects may be offered:
(i) First of all the efficacy may be due to the reduction of
day 3 tumour load by CY prior to the administration of
IL-2. This reduction may be to such a low level of tumour
load that treatment with low dose IL-2 will have a further
significant tumour reducing effect. It is well known that
many biologicals, when used alone, exert significant anti-
tumour effects only when the tumour load is small (Bast &
Bast, 1976; Eggermont et al., 1986a). It is important to
realize that the dose of CY, as used in our experiments, has
no negative effect on in vivo activation of NK cells (Li et al.,
1987).
(ii) The effect of the administration of CY on day 3 may
be due to its damage to tumour cells to such a degree that
they become more susceptible to lysis by LAK cells, as has
been suggested by Papa and coworkers (1988). Conversely
immunotherapy may render tumour cells more susceptible to
subsequent chemotherapy (Ades et al., 1987), which might
explain the efficacy of the administration of a second dose of
CY on day 8 in our experiments.
(iii) The significant impact of a second dose of CY on day
8 may well reflect a different mechanism that can potentiate
the effects of immunotherapy. Several authors have sug-
gested that a most important mechanism by which CY can
enhance immunotherapeutic regimens is by removal of sup-
pressor cells (Polak & Turk, 1974; North, 1982; Greenberg et
al., 1985). It has been shown very elegantly by North (1984)
that suppressor cells play an increasingly important role
seven or more days after tumour inoculation, and that their
removal facilitates adoptive immunotherapy.
(iv) Alternatively one may hypothesize that the abrogation
of the primary immune response by cyclophosphamide
(Anderson et al., 1986; Eggermont et al., 1986b) to a weakly
immunogenic tumour like MCA-105 removes the cytotoxic
T-lymphocytes and thereby an immune cell population that
can compete with LAK cells for IL-2. We have demon-
strated this phenomenon in vitro (Sugarbaker et al., 1987a)
and reported previously that it can play an important role in
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Figure 2 Combination tretment with CY, IL-2 and LAK cells prolongs survival most effectively qfter high dose tumour inoculation.
BL/6 mice, inoculated with the high dose of 3 x 105 MCA-105 tumour cells i.p. on day 0 were treated with 1 x 108 LAK cells on
day 3 and/or with IL-2 (25,000 Units, i.p., b.i.d.) from day 3 through 7 and/or with cyclophosphamide (CY) (50mgkg- 1, i.p.) on
day 3 and on day 8. P2-values for the significance of pairwise comparisons are indicated in the right upper corner. Combination
treatment with CY, IL-2 and LAK cells is clearly superior to any other treatment schedule.414 A.M.M. EGGERMONT & P.H. SUGARBAKER
vivo in the outcome of treatment with IL-2 and LAK cells
(Eggermont et al., 1987b).
(v) Finally the hepatotoxic and nephrotoxic effects of IL-2
(Matory et al., 1985) may have altered considerably the
pharmacokinetics and metabolism of CY (given on day 8)
and may thus have influenced its half life and enhanced its
tumour kill.
In conclusion, we have shown that the efficacy of adoptive
immunotherapy with low to moderate doses of IL-2 in
conjunction with the adoptive transfer of LAK cells can be
greatly enhanced by the administration of low doses of
cyclophosphamide. This is of importance since the toxicity
associated with high doses of IL-2 is quite severe and a
major obstacle in obtaining cures with immunotherapeutic
regimens alone (Matory et al., 1985; Lotze et al., 1986). In
view of the efficacy of a second dose of CY we are currently
concentrating our efforts on the development of more effec-
tive treatment schedules with repetitive treatment cycles.
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